SB 331750

a cathepsin K inhibitor; structure in first source

Also Known As:

5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-(3-oxo-1-(2-(3-pyridin-2-yl-phenyl)-ethenoyl)-azepan-4-ylcarbanoyl)-butyl)-amide; SB-331750; SB331750

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - SB 331750: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - SB 331750: 2

Experts

1.	Bolognese, Brian J: 1 article (06/2008)
2.	Capper-Spudich, Elizabeth A: 1 article (06/2008)
3.	Carpenter, Donald C: 1 article (06/2008)
4.	Davis, T Gregg: 1 article (06/2008)
5.	Dong, Xiaoyang: 1 article (06/2008)
6.	Fox, Josephine H: 1 article (06/2008)
7.	Johanson, Roy A: 1 article (06/2008)
8.	Kurali, Edit: 1 article (06/2008)
9.	Locastro, Stephen M: 1 article (06/2008)
10.	Long, Edward: 1 article (06/2008)

Related Diseases

1.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/15/2008 - "Similarly, treatment of myelin basic protein-primed SJL/J lymph node cells with SB-331750 delayed the onset and reduced the severity of adoptively transferred experimental autoimmune encephalomyelitis (EAE). "
2.	Experimental Arthritis 06/15/2008 - "Prophylactic administration of SB-331750 to collagen-immunized/boosted DBA/1 mice delayed the onset and reduced the severity of collagen-induced arthritis (CIA), and reduced paw tissue levels of IL-1beta and TNF-alpha. "
3.	Bone Resorption 05/01/2002 - "Together, these data indicate that the cathepsin K inhibitor, SB 331750, prevented bone resorption in vivo and this inhibition resulted in prevention of ovariectomy-induced loss in trabecular structure." 05/01/2002 - "In vitro, SB 331750 partially, but dose-dependently, prevented the parathyroid hormone-induced hypercalcemia in an acute rat model of bone resorption. " 05/01/2002 - "In an in situ enzyme assay, SB 331750 inhibited osteoclast-associated cathepsin activity in tissue sections containing human osteoclasts (IC(50) approximately 60 nmol/L) and this translated into potent inhibition of human osteoclast-mediated bone resorption in vitro (IC(50) approximately 30 nmol/L). " 05/01/2002 - "In this study, a potent, nonpeptide inhibitor of rat cathepsin K (K(i) = 4.7 nmol/L), 5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-(3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-ethenoyl]-azepan-4-ylcarbanoyl)-butyl)-amide (SB 331750), is described, which is efficacious in rat models of bone resorption. "
4.	Hypercalcemia (Milk Alkali Syndrome) 05/01/2002 - "In vitro, SB 331750 partially, but dose-dependently, prevented the parathyroid hormone-induced hypercalcemia in an acute rat model of bone resorption. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Myelin Basic Protein
3.	Collagen
4.	Cathepsin K
5.	Amides
6.	Acids
7.	Parathyroid Hormone (Parathormone)
8.	Enzymes
9.	Cathepsins

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)